SCYX - scynexia

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
quota sotto l'offerta pubblica di giugno, a maggio orphan drug designation, cash 38 milioni
sembra vicina a una svolta, ieri primo segnale ma per un inversione bisogna superare i 2.80
 

Allegati

  • scyx day.png
    scyx day.png
    74,9 KB · Visite: 504
  • scyx.png
    scyx.png
    62,6 KB · Visite: 506

agapemilano

Nuovo Utente
Registrato
27/7/13
Messaggi
1.328
Punti reazioni
23
quota sotto l'offerta pubblica di giugno, a maggio orphan drug designation, cash 38 milioni
sembra vicina a una svolta, ieri primo segnale ma per un inversione bisogna superare i 2.80

ma hanno fatto adc a giugno con 38 mln in cassa?
 

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
Cash and cash equivalents totaled $38.0 million as of March 31, 2016


Jun 21, 2016

SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share sold in the offering, before underwriting discounts and commissions. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $22.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. All of the shares of common stock and warrants are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock and warrants to purchase up to 632,812 shares of common stock at the public offering price less the underwriting discounts and commissions solely to cover over-allotments, if any.


The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.00 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and SCYNEXIS does not expect a market to develop.
 

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
bella partenza e 3.07 da bucare in chiusura.
 

buythedeep

Nuovo Utente
Registrato
4/2/15
Messaggi
1.006
Punti reazioni
8
Sta salendo senza news giusto? Mi metto a 2.5
 

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s novel triterpenoid broad-spectrum antifungal agent, SCY-078, for the treatment of invasive Aspergillus infections.


The orphan drug designation of SCY-078 provides seven years of market exclusivity in the U.S. following FDA approval of an NDA for the orphan designated indication. This is the second U.S. orphan designation received for SCY-078. Earlier this year, the Company announced that SCY-078 received orphan drug designation for the treatment of invasive Candida infections, including candidemia. The Company was previously granted Qualified Infectious Disease Product (QIDP) designation for both the IV and oral formulations of SCY-078, which provides an additional five years of exclusivity. Together, these designations provide SCYNEXIS with a potential 12 years of market exclusivity in the U.S. upon FDA approval.

"The FDA's decision to grant SCY-078 orphan drug designation for invasive Aspergillus infections is another important milestone in the development of our lead compound recognizing the broad antifungal spectrum of this novel antifungal agent. We believe SCY-078 has the potential to be a unique treatment option for patients with acute and chronic fungal infections caused by Aspergillus," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "SCY-078 has clinically-relevant attributes such as high tissue penetration and distribution, reduced risk for drug-drug interactions, activity against azole-resistant pathogens and versatile administration with both oral and IV formulations. If approved, SCY-078 would currently be the only alternative to azoles to treat invasive Aspergillus infections (including azole-resistant strains), with the flexibility of both oral and IV formulations."

In the U.S., under the Orphan Drug Act, the FDA's Office of Orphan Products Development grants orphan drug designation to products intended to treat rare diseases or conditions, which are defined by the FDA as those affecting fewer than 200,000 people in the U.S.. In addition to the potential U.S. market exclusivity in the specified indication, if SCYNEXIS complies with certain FDA requirements, the designation provides several benefits and incentives, including tax credits related to qualified clinical trial expenses, eligibility for orphan drug grants, and an exemption from FDA application fees.
 

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
ocio alla rottura del bordo superiore della cloud, sma 200 nel mirino.
 

Allegati

  • scyx.png
    scyx.png
    77,4 KB · Visite: 368

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
brekkata la bollinger superiore con volumi in aumento da 2 sedute OK!
 

Allegati

  • scyx.png
    scyx.png
    77,3 KB · Visite: 272

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
bene bene.....Scynexis Inc. (NASDAQ:SCYX) Director Patrick Machado acquired 40,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was purchased at an average price of $2.94 per share, for a total transaction of $117,600.00. Following the purchase, the director now owns 60,000 shares of the company’s stock, valued at approximately $176,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

guardando il settimanale sembra pronta per i 5 ma forse anche qualcosa di più.
 

Allegati

  • scyx week.png
    scyx week.png
    75,8 KB · Visite: 268

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
c'è poco da commentare OK!
 

Allegati

  • SCYX.png
    SCYX.png
    33,9 KB · Visite: 243

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
brekkata la sma 200 :clap:
 

Allegati

  • scyx.png
    scyx.png
    80,9 KB · Visite: 216

davicerr

Nuovo Utente
Registrato
23/4/09
Messaggi
4.890
Punti reazioni
63
Bella davvero questa, peccato non averla vista prima... ormai aspetto il prossimo ritracciamento, è sulla sma200 in ipercomprato, a breve potrebbe rifiatare
 

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
brekka la resistenza a 4 con volumi e arrivano rating con target importanti OK!

Brean Capital assumed coverage of SCYNEXIS Inc SCYX 17.57% with a Buy rating and target price of $16, implying a potential upside of 313 percent.
Scynexis is focusing on the unmet needs surrounding resistant fungal infections. Its lead product candidate, SCY-078, is triterpene glucan synthase inhibitor, with potential for step down treatment in invasive candidiasis (IC) and invasive aspergillosis (IA).
In trials, SCY-078 has showed potent and broad spectrum anti-fungal activity, importantly against echinocandin-resistant strains, and a promising safety profile.
"We expect US and EU launches for IC and IA indications in 2019 and 2020 respectively, as well as a 2020 launch for SCY-078 vs. vulvovaginal candidiasis (VVC)," analyst Difei Yang wrote in a note.
Yang sees peak year revenue in the $300 million range with better-than-average success in product development.

The near-term catalysts include readout of Phase I trial identifying an optimal IV formulation of SCY-078 in November 2016 and the FDA meeting expected in the fourth quarter 2016/first quarter 2017.
Investors should also look for the initiation of a Phase 3 trial for refractory invasive fungal infections (rIFI) in the fourth quarter, and the anticipated first quarter initiation of the Phase II IC study. The top-line data from both studies are expected in the fourth quarter of 2017
 

Allegati

  • scyx.png
    scyx.png
    83,7 KB · Visite: 186

Paolino967

L'AQUILA
Registrato
7/1/01
Messaggi
5.978
Punti reazioni
176
Rientrato sulla 50 a 3,98, speriamo che tenga :(
 

Avio

AUTOSOSPESO
Sospeso dallo Staff
Registrato
20/7/01
Messaggi
88.895
Punti reazioni
1.741